Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 166,100 shares, an increase of 2,002.5% from the January 31st total of 7,900 shares. Based on an average trading volume of 175,600 shares, the short-interest ratio is presently 0.9 days. Approximately 0.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in Kamada in the fourth quarter worth about $67,000. Public Employees Retirement System of Ohio purchased a new position in shares of Kamada during the 3rd quarter worth approximately $77,000. Plato Investment Management Ltd bought a new position in shares of Kamada in the 3rd quarter worth approximately $117,000. NewEdge Advisors LLC lifted its stake in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Friday, January 10th.

Kamada Stock Down 2.7 %

Shares of Kamada stock opened at $6.91 on Friday. The company has a market cap of $397.19 million, a PE ratio of 24.68, a P/E/G ratio of 0.97 and a beta of 0.99. The business has a 50 day moving average of $7.01 and a 200 day moving average of $6.10. Kamada has a 52 week low of $4.74 and a 52 week high of $9.15.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.